
Annual report 2024
added 12-13-2025
Enlivex Therapeutics Ltd. Net Debt 2011-2025 | ENLV
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Enlivex Therapeutics Ltd.
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | -7.29 M | -10.6 M | -5.55 M | -146 K | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -146 K | -10.6 M | -5.89 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
ARCA biopharma
ABIO
|
-60.6 M | - | 1052.0 % | $ 415 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
469 M | $ 25.27 | -2.43 % | $ 1.22 B | ||
|
MorphoSys AG
MOR
|
163 M | - | 2.43 % | $ 254 M | ||
|
Alpine Immune Sciences
ALPN
|
-63.9 M | - | - | $ 2.17 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
-107 M | $ 4.75 | 1.61 % | $ 788 M | ||
|
Aclaris Therapeutics
ACRS
|
-22 M | $ 3.26 | -3.12 % | $ 252 M | ||
|
AlloVir
ALVR
|
-62.7 M | - | 4.14 % | $ 49.1 M | ||
|
Acasti Pharma
ACST
|
-27.4 M | - | 4.01 % | $ 150 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
-119 M | - | -15.15 % | $ 60.3 M | ||
|
Ampio Pharmaceuticals
AMPE
|
-12 M | - | -11.43 % | $ 502 K | ||
|
Aeglea BioTherapeutics
AGLE
|
-30.2 M | - | - | $ 1.01 B | ||
|
Kamada Ltd.
KMDA
|
-70.2 M | $ 7.03 | 0.14 % | $ 260 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
-402 M | - | - | $ 40.3 B | ||
|
Ascendis Pharma A/S
ASND
|
-195 M | $ 220.27 | 4.81 % | $ 5 B | ||
|
Albireo Pharma
ALBO
|
-239 M | - | -0.23 % | $ 916 M | ||
|
Ayala Pharmaceuticals
AYLA
|
-657 K | - | - | $ 7.46 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
-3.5 M | $ 0.28 | -2.28 % | $ 609 M | ||
|
Alterity Therapeutics Limited
ATHE
|
-34.7 M | $ 3.3 | -3.51 % | $ 7.94 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-824 K | - | -1.52 % | $ 24.7 M | ||
|
AstraZeneca PLC
AZN
|
9.86 B | $ 89.78 | -0.57 % | $ 96.9 B | ||
|
Midatech Pharma plc
MTP
|
-6.17 M | - | -18.52 % | $ 27.3 M | ||
|
Anika Therapeutics
ANIK
|
-46 M | $ 9.57 | 0.84 % | $ 140 M | ||
|
Brickell Biotech
BBI
|
-29.7 M | - | -5.38 % | $ 6.06 M | ||
|
BeiGene, Ltd.
BGNE
|
-2.44 B | - | 0.49 % | $ 251 B | ||
|
Bellicum Pharmaceuticals
BLCM
|
-34.7 M | - | -9.72 % | $ 5.89 M | ||
|
Berkeley Lights
BLI
|
-60.5 M | - | -7.31 % | $ 87 M | ||
|
Benitec Biopharma
BNTC
|
-1.92 M | $ 12.05 | -7.06 % | $ 496 M | ||
|
Aytu BioScience
AYTU
|
-19.9 M | $ 2.34 | 2.59 % | $ 14.7 M | ||
|
Nymox Pharmaceutical Corporation
NYMX
|
-7.95 M | - | -19.68 % | $ 18.4 M | ||
|
Arena Pharmaceuticals
ARNA
|
-25.4 M | - | -6.81 % | $ 3.04 B | ||
|
Aptorum Group Limited
APM
|
-2.77 M | $ 1.29 | -3.01 % | $ 7.03 M | ||
|
Biophytis SA
BPTS
|
-4.01 M | - | -13.47 % | $ 169 M | ||
|
Baudax Bio
BXRX
|
1.86 M | - | 0.59 % | $ 63 K | ||
|
Avenue Therapeutics
ATXI
|
-3.13 K | - | -52.27 % | $ 4.45 M | ||
|
Институт стволовых клеток человека
ISKJ
|
246 M | - | - | - | ||
|
Catalyst Biosciences
CBIO
|
-33.1 M | $ 14.01 | -8.49 % | $ 922 M | ||
|
ChromaDex Corporation
CDXC
|
-26.5 M | - | -0.88 % | $ 598 M | ||
|
Axon Enterprise
AXON
|
-404 M | $ 566.18 | -2.56 % | $ 42.9 B | ||
|
Cerus Corporation
CERS
|
-6.33 M | $ 2.16 | 0.47 % | $ 399 M | ||
|
Checkpoint Therapeutics
CKPT
|
-40.8 M | - | - | $ 169 M | ||
|
Caladrius Biosciences
CLBS
|
-22.3 M | - | -16.75 % | $ 25.8 M | ||
|
Clovis Oncology
CLVS
|
293 M | - | -7.23 % | $ 13 M | ||
|
Biogen
BIIB
|
4.01 B | $ 174.42 | 1.11 % | $ 25.4 B | ||
|
BioVie
BIVI
|
-17.2 M | $ 1.42 | -5.96 % | $ 2.1 M | ||
|
Celldex Therapeutics
CLDX
|
-24.5 M | $ 27.36 | -2.09 % | $ 1.76 M | ||
|
Cortexyme
CRTX
|
-68.6 M | - | -1.05 % | $ 67.1 M | ||
|
Cellectar Biosciences
CLRB
|
-9.01 M | $ 3.63 | -3.97 % | $ 44.4 M | ||
|
Deciphera Pharmaceuticals
DCPH
|
-57.6 M | - | - | $ 2.18 B | ||
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
455 M | $ 11.54 | 0.87 % | $ 746 M |